The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Clinical significance of MRD status in patients with MM treated with CAR-T and T-cell engagers
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the clinical significance of measurable residual disease (MRD) in patients with relapsed/refractory (R/R) multiple myeloma (MM) who are treated with CAR-T cells and T-cell engagers. Dr Paiva notes that the role of MRD in the era of newer immunotherapies is uncertain. Data from an analysis of patients showed that, although achieving MRD negativity was the most relevant prognostic factor, it may not hold the same significance as a clinical endpoint that it does with other treatment options. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Roche Glycart AG, Janssen, Sanofi, GSK, Takeda, Adaptive, Amgen, Bristol-Myers Squibb, Gilead, Oncopeptides
Research Funding: Roche Glycart AG, Sanofi, EngMab, GSK, Takeda, Bristol-Myers Squibb
Consultancy: Janssen, Sanofi, Bristol-Myers Squibb
